Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Lee, Soon Il | - |
dc.contributor.author | Won, Jong Ho | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Kwon, Jung Hye | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Kwon, Jung Mi | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Oh, Sukjoong | - |
dc.contributor.author | Park, Keon Woo | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Kim, Won Seog | - |
dc.date.accessioned | 2021-09-07T10:06:38Z | - |
dc.date.available | 2021-09-07T10:06:38Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2011-07-29 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111958 | - |
dc.description.abstract | Background: Primary intestinal non-Hodgkin lymphoma (NHL) is a heterogeneous disease with regard to anatomic and histologic distribution. Thus, analyses focusing on primary intestinal NHL with large number of patients are warranted. Methods: We retrospectively analyzed 581 patients from 16 hospitals in Korea for primary intestinal NHL in this retrospective analysis. We compared clinical features and treatment outcomes according to the anatomic site of involvement and histologic subtypes. Results: B-cell lymphoma (n = 504, 86.7%) was more frequent than T-cell lymphoma (n = 77, 13.3%). Diffuse large B-cell lymphoma (DLBCL) was the most common subtype (n = 386, 66.4%), and extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) was the second most common subtype (n = 61, 10.5%). B-cell lymphoma mainly presented as localized disease (Lugano stage I/II) while T-cell lymphomas involved multiple intestinal sites. Thus, T-cell lymphoma had more unfavourable characteristics such as advanced stage at diagnosis, and the 5-year overall survival (OS) rate was significantly lower than B-cell lymphoma (28% versus 71%, P < 0.001). B symptoms were relatively uncommon (20.7%), and bone marrow invasion was a rare event (7.4%). The ileocecal region was the most commonly involved site (39.8%), followed by the small (27.9%) and large intestines (21.5%). Patients underwent surgery showed better OS than patients did not (5-year OS rate 77% versus 57%, P < 0.001). However, this beneficial effect of surgery was only statistically significant in patients with B-cell lymphomas (P < 0.001) not in T-cell lymphomas (P = 0.460). The comparison of survival based on the anatomic site of involvement showed that ileocecal regions had a better 5-year overall survival rate (72%) than other sites in consistent with that ileocecal region had higher proportion of patients with DLBCL who underwent surgery. Age > 60 years, performance status >= 2, elevated serum lactate dehydrogenase, Lugano stage IV, presence of B symptoms, and T-cell phenotype were independent prognostic factors for survival. Conclusions: The survival of patients with ileocecal region involvement was better than that of patients with involvement at other sites, which might be related to histologic distribution, the proportion of tumor stage, and need for surgical resection. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BIOMED CENTRAL LTD | - |
dc.subject | INTERNATIONAL PROGNOSTIC INDEX | - |
dc.subject | B-CELL LYMPHOMA | - |
dc.subject | GIT NHL 01/92/ | - |
dc.subject | CLINICAL-FEATURES | - |
dc.subject | GASTROINTESTINAL LYMPHOMA | - |
dc.subject | GERMAN MULTICENTER | - |
dc.subject | CLINICOPATHOLOGICAL ANALYSIS | - |
dc.subject | MALIGNANT-LYMPHOMAS | - |
dc.subject | GASTRIC-LYMPHOMA | - |
dc.subject | TRACT LYMPHOMA | - |
dc.title | Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.identifier.doi | 10.1186/1471-2407-11-321 | - |
dc.identifier.scopusid | 2-s2.0-79960883662 | - |
dc.identifier.wosid | 000294180200002 | - |
dc.identifier.bibliographicCitation | BMC CANCER, v.11 | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.citation.title | BMC CANCER | - |
dc.citation.volume | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | INTERNATIONAL PROGNOSTIC INDEX | - |
dc.subject.keywordPlus | B-CELL LYMPHOMA | - |
dc.subject.keywordPlus | GIT NHL 01/92/ | - |
dc.subject.keywordPlus | CLINICAL-FEATURES | - |
dc.subject.keywordPlus | GASTROINTESTINAL LYMPHOMA | - |
dc.subject.keywordPlus | GERMAN MULTICENTER | - |
dc.subject.keywordPlus | CLINICOPATHOLOGICAL ANALYSIS | - |
dc.subject.keywordPlus | MALIGNANT-LYMPHOMAS | - |
dc.subject.keywordPlus | GASTRIC-LYMPHOMA | - |
dc.subject.keywordPlus | TRACT LYMPHOMA | - |
dc.subject.keywordAuthor | intestine | - |
dc.subject.keywordAuthor | non-Hodgkin lymphoma | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | histopathology | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.